S&P 500   3,953.27 (-0.26%)
DOW   33,647.17 (-0.40%)
QQQ   284.26 (+0.14%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.85 (-4.18%)
BABA   92.35 (-1.93%)
AMD   69.64 (-1.18%)
T   19.20 (+0.42%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.26 (-1.64%)
DIS   94.13 (+1.71%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   325.08 (+4.78%)
S&P 500   3,953.27 (-0.26%)
DOW   33,647.17 (-0.40%)
QQQ   284.26 (+0.14%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.85 (-4.18%)
BABA   92.35 (-1.93%)
AMD   69.64 (-1.18%)
T   19.20 (+0.42%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.26 (-1.64%)
DIS   94.13 (+1.71%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   325.08 (+4.78%)
S&P 500   3,953.27 (-0.26%)
DOW   33,647.17 (-0.40%)
QQQ   284.26 (+0.14%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.85 (-4.18%)
BABA   92.35 (-1.93%)
AMD   69.64 (-1.18%)
T   19.20 (+0.42%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.26 (-1.64%)
DIS   94.13 (+1.71%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   325.08 (+4.78%)
S&P 500   3,953.27 (-0.26%)
DOW   33,647.17 (-0.40%)
QQQ   284.26 (+0.14%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.85 (-4.18%)
BABA   92.35 (-1.93%)
AMD   69.64 (-1.18%)
T   19.20 (+0.42%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.26 (-1.64%)
DIS   94.13 (+1.71%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   325.08 (+4.78%)
NASDAQ:ENTA

Enanta Pharmaceuticals - ENTA Stock Forecast, Price & News

$42.10
+0.14 (+0.33%)
(As of 12/9/2022 01:55 PM ET)
Add
Compare
Today's Range
$41.50
$42.71
50-Day Range
$41.05
$53.73
52-Week Range
$37.59
$80.40
Volume
917 shs
Average Volume
163,607 shs
Market Capitalization
$875.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$67.43

Enanta Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
58.5% Upside
$66.00 Price Target
Short Interest
Bearish
5.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.07
Upright™ Environmental Score
News Sentiment
0.59mentions of Enanta Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.36) to $0.13 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

360th out of 1,022 stocks

Pharmaceutical Preparations Industry

152nd out of 499 stocks

ENTA stock logo

About Enanta Pharmaceuticals (NASDAQ:ENTA) Stock

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENTA Stock News Headlines

Earnings Outlook For Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. (ENTA)
See More Headlines
Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENTA Company Calendar

Last Earnings
11/21/2022
Today
12/09/2022
Next Earnings (Estimated)
2/06/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENTA
Employees
155
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$66.00
High Stock Price Forecast
$96.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+60.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
7 Analysts

Profitability

Net Income
$-121,750,000.00
Net Margins
-141.31%
Pretax Margin
-141.82%

Debt

Sales & Book Value

Annual Sales
$86.16 million
Book Value
$15.51 per share

Miscellaneous

Free Float
18,355,000
Market Cap
$875.68 million
Optionable
Optionable
Beta
0.51

Key Executives

  • Dr. Jay R. LulyDr. Jay R. Luly (Age 66)
    Pres, CEO & Director
    Comp: $1.23M
  • Mr. Paul J. Mellett Jr.Mr. Paul J. Mellett Jr. (Age 67)
    Sr. VP of Fin. & Admin. and CFO
    Comp: $652.39k
  • Dr. Yat Sun Or Ph.D. (Age 70)
    Sr. VP of R&D and Chief Scientific Officer
    Comp: $729.75k
  • Ms. Tara Lynn Kieffer Ph.D. (Age 44)
    Sr. VP of New Product Strategy & Devel.
    Comp: $496.85k
  • Mr. Brendan Luu
    Sr. VP of Bus. Devel.
  • Ms. Jennifer Viera
    Sr. Director of Investor Relations & Corp. Communications
  • Mr. Nathaniel S. Gardiner J.D. (Age 68)
    Sr. VP, Gen. Counsel & Sec.
  • Dr. Nathalie Adda M.D. (Age 56)
    Consultant
  • Dr. Scott T. Rottinghaus
    Sr. VP & Chief Medical Officer













ENTA Stock - Frequently Asked Questions

Should I buy or sell Enanta Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ENTA shares.
View ENTA analyst ratings
or view top-rated stocks.

What is Enanta Pharmaceuticals' stock price forecast for 2023?

6 brokerages have issued 12 month price targets for Enanta Pharmaceuticals' shares. Their ENTA share price forecasts range from $50.00 to $96.00. On average, they expect the company's stock price to reach $67.43 in the next twelve months. This suggests a possible upside of 60.7% from the stock's current price.
View analysts price targets for ENTA
or view top-rated stocks among Wall Street analysts.

How have ENTA shares performed in 2022?

Enanta Pharmaceuticals' stock was trading at $74.78 at the beginning of the year. Since then, ENTA shares have decreased by 43.9% and is now trading at $41.96.
View the best growth stocks for 2022 here
.

When is Enanta Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 6th 2023.
View our ENTA earnings forecast
.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) issued its quarterly earnings results on Monday, November, 21st. The biotechnology company reported ($1.27) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.10. The biotechnology company earned $20.32 million during the quarter, compared to analysts' expectations of $22.86 million. Enanta Pharmaceuticals had a negative net margin of 141.31% and a negative trailing twelve-month return on equity of 34.73%. Enanta Pharmaceuticals's revenue was down 13.8% on a year-over-year basis. During the same period in the previous year, the business earned ($1.22) earnings per share.

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (17.47%), Armistice Capital LLC (10.00%), Vanguard Group Inc. (7.13%), State Street Corp (6.65%), Dimensional Fund Advisors LP (2.46%) and Renaissance Technologies LLC (2.26%). Insiders that own company stock include Bruce L A Carter, Jay R Luly, Nathalie Adda and Paul J Mellett.
View institutional ownership trends
.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $41.96.

How much money does Enanta Pharmaceuticals make?

Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $872.64 million and generates $86.16 million in revenue each year. The biotechnology company earns $-121,750,000.00 in net income (profit) each year or ($5.91) on an earnings per share basis.

How many employees does Enanta Pharmaceuticals have?

The company employs 155 workers across the globe.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at cmiceli@enanta.com, or via fax at 617-607-0530.

This page (NASDAQ:ENTA) was last updated on 12/9/2022 by MarketBeat.com Staff